New Zealand Autism Spectrum Disorder Guideline - Ministry of Health

New Zealand Autism Spectrum Disorder Guideline 301
Please note this is intended as a guide only. Clinicians should consult other appropriate references for comprehensive information on adverse effects and interactions.
Table 9.1: Drugs used in ASD
(adapted with permission from CAMHSNET 430 )
Generic name Trade name NZ prescribing information Recommended dose range Adverse effects Important interactions
Atypical Antipsychotics
Risperidone Risperdal Oral liquid: 1mg/ml
Tablet: 0.5mg, 1mg, 2mg, 3mg, 4mg
Orally disintegrating tablets: 0.5mg,
1mg, 2mg (Special Authority criteria
apply)
Retail pharmacy – Specialist
Fully subsidised
Olanzapine Zyprexa Tablet: 2.5mg, 5mg, 10mg
Orodispersible wafer 5mg, 10mg
Retail pharmacy – Special Authority
– application only by Psychiatrist
Fully subsidised
Quetiapine Seroquel Tablet: 25mg, 100mg, 150mg, 200mg
See prescribing advice in
Pharmaceutical Schedule.
Fully subsidised
Appendices
0.015mg/kg/day to 0.05mg/kg/
day in two divided doses
0.1 to 0.25 mg/kg/day in 2 divided
doses. Max 20mg per day in
adolescents>40kg
0.25 to 8 mg/kg/day in 2 divided
doses
• Weight gain
• Extrapyramidal side effects [EPSE]
(worse at higher dosage)
• Akathisia (esp. adolescents)
• Sedation
• Insomnia
• Type 2 diabetes mellitus
• Sialorrhoea
• Enuresis, rhinitis, epistaxis
• Sexual dysfunction, priapism
As for risperidone, but weight gain
and type 2 diabetes more likely and
EPSE less likely.
As for risperidone.
Agitation commonly reported in
adults.
Carbamazepine ( levels of RISP)
SSRIs
( levels of RISP & SSRI) unlikely
clinically significant but watch for
serotonin toxicity
Appendix 9:Drugs used in ASD
Appendices